From a molecular point of view, oncogenic activation of the mitogen-activated protein kinase (MAPK) pathway, due to somatic mutations in B-RAF (V600E), is frequently observed in melanoma (70%) [4]. The gene discussed is BRAF; the disease is melanoma.